Skip to main content

Updated from 8:55 a.m. EDT


Flamel Technologies


was bid up sharply in premarket trading after



Scroll to Continue

TheStreet Recommends

anointed a diabetes treatment it's developing.

The companies entered a licensing and commercialization agreement covering Flamel's Basulin, a controlled-release form of insulin that is about to enter phase II clinical trials. The agreement calls for Bristol-Myers to assume the cost of future development and manufacturing of the drug, in return for exclusive worldwide rights to it.

Bristol-Myers will pay Flamel $20 million now and $145 million when certain milestones are reached. It will also pay "double-digit royalties" to Flamel when and if the treatment hits the market.

Flamel closed Wednesday at $26.95 on the



The pact needs antitrust approval.